Skip to main content
Clinical Trials/NCT02960464
NCT02960464
Unknown
Not Applicable

Transcranial Direct Current Stimulation for Treatment of Depression in Parkinson's Disease, a Randomized Placebo-controlled Clinical Trial

Hospital Santa Marcelina1 site in 1 country50 target enrollmentOctober 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Idiopathic Parkinson Disease
Sponsor
Hospital Santa Marcelina
Enrollment
50
Locations
1
Primary Endpoint
Hamilton Rating Scale for Depression
Last Updated
9 years ago

Overview

Brief Summary

Investigation of possible benefits of transcranial direct current stimulation (tDCS) as a treatment of depression in patients with Parkinson's Disease, through a randomized placebo-controlled clinical trial.

Detailed Description

We aim to investigate the effects of transcranial direct current stimulation (tDCS) as treatment for depression in patients with Parkinson's Disease. We have designed a clinical trial in which volunteers that fulfill inclusion criteria will receive 15 sessions of tDCS during 1 week (3 sessions a day, with 30 minutes interval in between). Subjects will be randomly allocated into two groups, one that will receive the real intervention (active) and the other that will receive the placebo intervention (sham). The collaborator in charge of administering the session will not participate in the evaluations, keeping both subjects and evaluators blinded to the nature of the sessions. Subjects will be evaluated at baseline, and after the end of sessions, 1 week, 4 weeks and 8 weeks, the latter being the main outcome. We aim to enroll 50 subjects, 25 for each arm. The sample size calculation took into consideration previous clinical trials using tDCS for depression in different settings.

Registry
clinicaltrials.gov
Start Date
October 2016
End Date
June 2018
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Pedro Caldana Gordon

Principal Investigator

Hospital Santa Marcelina

Eligibility Criteria

Inclusion Criteria

  • Idiopathic Parkinson's Disease
  • Geriatric Depression Scale - 15 higher that 5
  • Major Depression Disorder

Exclusion Criteria

  • CNS disease other than Parkinson's Disease (i.e. epilepsy, stroke)
  • Mental disorder other than depression on anxiety disorder (i.e. bipolar disorder, schizophrenia)
  • Previous neurosurgical intervention (i.e. DBS)
  • Current use of antidepressant drug
  • High suicidality risk
  • Limited capacity of understanding written and spoken Portuguese

Outcomes

Primary Outcomes

Hamilton Rating Scale for Depression

Time Frame: 8 weeks

Secondary Outcomes

  • Quantitative EEG(8 weeks)
  • Geriatric Depression Scale -15(8 weeks)
  • Parkinson's Disease Questionnaire - 39(8 weeks)
  • Mini-Mental State Examination(8 weeks)
  • Hamilton Anxiety Rating Scale(8 weeks)
  • Montgomery-Åsberg Depression Rating Scale(8 weeks)
  • Lille apathy rating scale(8 weeks)

Study Sites (1)

Loading locations...

Similar Trials